Explore

Rapid Read Rapid Read
Massive Bio Collaborates with TOUCH and Navigating Trials to Enhance Cancer Patients' Access to Clinical Trials

Massive Bio Collaborates with TOUCH and Navigating Trials to Enhance Cancer Patients' Access to Clinical Trials

Massive Bio, a global precision oncology company, has announced a partnership with TOUCH, The Black Breast Cancer Alliance, and Navigating Trials to improve access to clinical trials for cancer patients. This collaboration will integrate Massive Bio's AI-powered trial matching system into the digital platforms of both organizations, providing a seamless and cost-free pathway for patients to find personalized clinical trial options. TOUCH BBCA focuses on supporting breast cancer patients through education and advocacy, while Navigating Trials extends clinical research opportunities to patients across various cancer types. The partnership aims to bridge the gap between patient communities and the clinical research ecosystem, ensuring equitable access to clinical trials.
Rapid Read Rapid Read
Johnson Johnson's Amivantamab Shows Promise in Eradicating Tumors in Cancer Patients

Johnson Johnson's Amivantamab Shows Promise in Eradicating Tumors in Cancer Patients

A recent international trial has demonstrated promising results for a cancer treatment developed by Johnson & Johnson. The treatment, known as amivantamab, was tested on patients whose cancer had spread or returned after failing to respond to other treatments. The trial, which spanned 11 countries, showed that the injection could shrink tumors in more than a third of patients, with dramatic changes observed within weeks. In 15 patients, the drug completely eradicated their tumors. The treatment targets cancer in three ways: blocking the epidermal growth factor receptor (EGFR), inhibiting the MET pathway, and activating the immune system to attack the tumor. The results of the trial will be presented at the American Society of Clinical Oncology's annual meeting in Chicago.
Trendline Trendline
Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients
Trendline Trendline
Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%

Akeso's Ivonescimab Shows Promising Results in Lung Cancer Treatment, Reducing Death Risk by 34%
Trendline Trendline
Ivonescimab Shows Improved Survival in Non-Small Cell Lung Cancer

Ivonescimab Shows Improved Survival in Non-Small Cell Lung Cancer

Ivonescimab Shows Improved Survival in Non-Small Cell Lung Cancer
Trendline Trendline
Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment

Johnson Johnson's Erleada Shows Promise in Prostate Cancer Treatment
Trendline Trendline
TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer
Reuters Reuters
Experimental Novartis radiopharma drug shows promise in early study

Experimental Novartis radiopharma drug shows promise in early study

By Bhanvi Satija May 31 (Reuters) - Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
Rapid Read Rapid Read
Jacksonville Girl Faces Cancer Relapse, Heads to NYC for Experimental Treatment

Jacksonville Girl Faces Cancer Relapse, Heads to NYC for Experimental Treatment

A 10-year-old girl from Jacksonville, Florida, named Gianna, is confronting a recurrence of bone cancer after nearly a year of being cancer-free. Initially diagnosed with osteosarcoma in November 2024, Gianna underwent significant medical treatment, including the amputation of her right leg. Despite being declared cancer-free last summer, recent scans revealed the cancer's return, manifesting as two nodules in her lungs and causing shoulder pain. With no standard treatment available for her relapse, Gianna has been accepted into an experimental trial at Memorial Sloan Kettering Cancer Center in New York City. The initial visit for this trial is expected to cost at least $7,000. To support the family with these expenses, a family friend has initiated a GoFundMe campaign.
Trendline Trendline
Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial, Potentially Expanding Treatment Options
Trendline Trendline
ConcertAI Enhances CancerLinQ Suite with AI-Driven Trial Matching

ConcertAI Enhances CancerLinQ Suite with AI-Driven Trial Matching

ConcertAI Enhances CancerLinQ Suite with AI-Driven Trial Matching
Rapid Read Rapid Read
BPGbio to Present Phase 2 Study Update on BPM31510 for Glioblastoma at ASCO 2026

BPGbio to Present Phase 2 Study Update on BPM31510 for Glioblastoma at ASCO 2026

BPGbio, a clinical-stage biopharmaceutical company, is set to present new clinical progress from its ongoing Phase 2 study of BPM31510 at the ASCO Annual Meeting in 2026. BPM31510 is a first-in-class therapeutic targeting tumor metabolism, specifically designed to reprogram the mitochondrial microenvironment in Warburg-avid tumors. The study focuses on patients with newly diagnosed glioblastoma multiforme (GBM) who have not received prior therapy. The investigational therapy combines a lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10) with vitamin K1, alongside standard-of-care radiation therapy and temozolomide. The aim is to modulate mitochondrial function, restore oxidative balance, and induce tumor-selective redox stress, potentially increasing the vulnerability of tumor cells in aggressive cancers like glioblastoma.